Treatment of advanced pancreatic carcinoma with a combination of protracted infusional 5-fluorouracil and weekly carboplatin: A Mid-Atlantic oncology program study

Annals of Oncology

Volumn 8, Issue 5, 1997, Pages 439-444

  Auerbach, M ^a   Wampler, G L ^b   Lokich, J J ^c   Fryer, D ^d   Fryer, J G ^d   Ahlgren, J D ^e  

^a Franklin Square Hospital Center   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Cancer Center   (United States)

^d IL   (United States)

^e GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Carboplatin; Fluorouracil; Pancreatic carcinoma; Response; Survival; Toxicity

Indexed keywords

BILIRUBIN; CARBOPLATIN; CHLORHEXIDINE; CREATININE; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD CELL COUNT; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; NEPHROTOXICITY; PANCREAS BIOPSY; PANCREAS CARCINOMA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0030878120     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008299429294     Document Type: Article

References (36)

1. Parker SL, Tong T, Bolden, S, Wingo PA, Cancer statistics, 1997. CA 1997; 47: 5-27.
2. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 54: 594-606.
3. Ahlgren JD, Hill MA, Roberts I. Pancreatic cancer: Patterns, diagnosis, and approach to treatment. In Ahlgren JD, Macdonald JS (eds): Gastrointestinal Oncology. Philadelphia: JB Lippincott 1992; 197-207.
4. O'Connll MJ. Current status of chemotherapy for advanced pancreatic and gastric cancer. J Clin Oncol 1985; 7: 1032-9.
5. Ahlgren JD. Chemotherapy for pancreatic cancer. Cancer 1996; 78: 654-63.
6. Smith FP, Hoth DF, Levin B et al. 5-Fluorouracil. Adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer 1980; 46: 2014-8.
7. Bitran JD, Desser RK, Kazloff MF et al. Treatment of metastalic pancreatic and gastric adenocarcinomas with 5-fluorouracil. Adriamycin, and mitomycin-C (FAM). Cancer Treat Rep 1979; 63: 2049-51.
8. Wiggans RG, Woolley PV, Macdonald JS et al. Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer. Cancer 1978; 41: 387-91.
9. Bukowski RM, Aberhalden RT, Hewlett JS et al. Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil in adenocarcinoma of the pancreas. Cancer Clin Trials 1980; 3: 321-4.
10. Theologides A, Cooper MR, Rafla S et al. Fluorouracil + Adriamycin + mitomycin-C in advanced pancreatic cancer. Proc Am Soc Clin Oncol 1982; 1: 90 (Abstr).
11. Gastrointestinal Tumor Study Group. Phase II studies of drug combinations in advanced pancreatic carcinoma: Fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. J Clin Oncol 1986; 4: 1794-8.
12. Oster MW, Gray R. Panasci L, Perry MC. Chemotherapy for advanced pancreatic cancer: A comparison of 5-fluorouracil. Adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM). Cancer 1986; 57: 29-33.
13. Lokich JJ, Ahlgren JD, Gullo J et al. A prospective randomized comparison of continuous infusion 5-fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. J Clin Oncol 1989; 7: 425-32.
14. Rooney M, Kish J, Jacobs J et al. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 1985; 55: 1123-8.
15. Amrein PC, Weitzman SA. Treatment of squamous-cell carcinoma of the head and neck with cisplatin and 5-fluorouracil. J Clin Oncol 1985; 3: 1632-9.
16. Scanlon KJ, Newman EM, Lu Y et al. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acac Sci USA 1986; 83: 8923-5.
17. Ortiz J, Woolley PV. A study of the synergistic cytotoxic effects of 5-fluorouracil and cisplatin against colon carcinoma cells using median effect analysis. Proc Am Assoc Cancer Res 1987; 28: 414 (Abstr).
18. Moertel CG. Rubin J, O'Connell MJ et al. A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 1986; 4: 1053-7.
19. Cullinan S, Moertel CG, Rieand HS et al. A phase III trial on the therapy of advanced pancreatic cancer: Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 1990; 65: 2207-12.
20. Lokich JJ, Ahlgren JD, Cantrell J et al. A prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. Cancer 1991; 67: 14-9.
21. Rothman H, Cantrell JE Jr. Lokich J et al. Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma: A Mid-Atlantic Oncology Program study. Cancer 1991; 68: 264-8.
22. Oken MM, Davis TE, Creech RH et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 549-655.
23. 2/d continuous 5-FU. Proc Am Soc Clin Oncol 1987; 6: 74 (Abstr).
24. Beveridge RA, Kales AN, Binder RA et al. Pyridoxine (B6) and amelioration of hand/foot syndrome. Proc Am Soc Clin Oncol 1990; 9: 102 (Abstr).
25. Vukelja SJ, Lombardo PA, James WD, Weiss RB. Pyridoxine for the palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1989; 111: 688-9 (Letter).
26. Glimelius B, Huffman K, Sjödén P-O et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600.
27. Burris HA, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997. in press.
28. Schein PS, Lavin PT, Moertel CG et al. Randomized phase II clinical trial of Adriamycin, methotrexate, and actimomycin-D in advanced measurable pancreatic carcinoma: A Gastrointestinal Tumor Study Group report. Cancer 1978; 42: 19-22.
29. Gastrointestinal Tumor Study Group. Phase II trials of maytansine. low-dose chlorozotocin, and high-dose chlorozotocin as single agents against advanced measurable adenocarcinoma of the pancreas. Cancer Treat Rep 1985; 69: 417-20.
30. Gastrointestinal Tumor Study Group. Phase II trials of hexamethylmelamine, dianhydrogalactitol, razoxane, and β-2'-deoxythioguanosine as single agents against advanced measurable tumors of the pancreas. Cancer Treat Rep 1985; 69: 713-6.
31. Cullinan SA, Moertel CG, Fleming TR et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric cancer: fluorouracil vs. fluorouracil and doxorubicin vs. Fluorouracil, doxorubicin. and mitomycin. JAMA 1985; 253: 2061-7.
32. Crown J, Casper ES, Botet J el al. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 1991; 9: 1682-6.
33. DeCaprio JA, Mayer RJ, Gonin R, Arbuck SG. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: Results of a phase II trial. J Clin Oncol 1991; 9: 2128-33.
34. Rubin J, Gallagher JG, Schroeder G et al. Phase II trials of 5-fluorouracil and leucovorin in patients with melastatic gastric or pancreatic carcinoma. Cancer 1996; 78: 1888-91.
35. Nicolson M, Webb A, Cunningham D et al. Cisplatin and protracted infusion 5-fluorouracil (CF) - good symptom relief with low toxicity in advanced pancreatic carcinoma. Ann Oncol 1995; 6: 801-4.
36. Hansen R, Quebbeman E, Rich P et al. Continuous 5-fluorouracil (5-FU) infusion in carcinoma of the pancreas: A phase II study. Am J Med Sci 1988; 295: 91-3.